Jazz Pharmaceuticals (JAZZ) Change in Receivables (2010 - 2026)

Jazz Pharmaceuticals' Change in Receivables history runs 17 years deep, the most recent figure standing at $6.5 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 109.85% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $178.8 million (up 435.24% YoY), while the FY2025 annual figure was $106.3 million, up 403.33% from the prior year.
• Change in Receivables was $6.5 million for Q1 2026 at Jazz Pharmaceuticals, down from $65.8 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $75.5 million in Q4 2023 to a low of -$66.0 million in Q1 2025.
• Historically, Change in Receivables has averaged $16.2 million across 5 years, with a median of $9.7 million in 2022.
• Biggest YoY gain for Change in Receivables was 7717.25% in 2025; the steepest drop was 881.71% in 2025.
• A 5-year view of Change in Receivables shows it stood at $46.3 million in 2022, then soared by 63.11% to $75.5 million in 2023, then plunged by 101.14% to -$864000.0 in 2024, then surged by 7717.25% to $65.8 million in 2025, then tumbled by 90.12% to $6.5 million in 2026.
• The last three Change in Receivables figures came in at $6.5 million (Q1 2026), $65.8 million (Q4 2025), and $51.0 million (Q3 2025), per Business Quant data.